HGG

Anova to Manage Study of DB107 Following Newly Awarded $11.8M CIRM Grant

Retrieved on: 
Wednesday, May 1, 2024
Other Health, Software, Research, Pharmaceutical, Philanthropy, Oncology, Technology, Foundation, Science, Biotechnology, Other Science, Health, FDA, University, UCSD, BTRC, Regenerative medicine, HGG, University of California, Partnership, Doctor of Philosophy, CIRM, UCSF, Patient, Analysis of variance, SOC, Enterprise, USC, Neuro

Anova Enterprises, Inc. (Anova), a technology enabled CRO dedicated to accelerating promising treatments, has collaborated with University of California at San Francisco (UCSF), University of California at San Diego (UCSD), the University of Southern California (USC) and Denovo Biopharma to manage a newly awarded $11.8M California Institute for Regenerative Medicine (CIRM) grant to support the development of DB107 in patients with newly diagnosed high-grade glioma.

Key Points: 
  • Anova Enterprises, Inc. (Anova), a technology enabled CRO dedicated to accelerating promising treatments, has collaborated with University of California at San Francisco (UCSF), University of California at San Diego (UCSD), the University of Southern California (USC) and Denovo Biopharma to manage a newly awarded $11.8M California Institute for Regenerative Medicine (CIRM) grant to support the development of DB107 in patients with newly diagnosed high-grade glioma.
  • DGM7 has been shown to be associated with increased overall survival with treatment of recurrent HGG, via retrospective analysis.
  • Anova was approached to assist with the development of the product and was instrumental organizing leading neuro-scientists, developing the study plans, securing FDA approval, preparing the CIRM application, and securing the ultimate CIRM award.
  • The Phase 1/2a clinical trial is a multicenter, open-label study designed to confirm whether treatment DB107, when added to standard-of-care (SOC), provides clinical benefit to patients with newly diagnosed HGG when compared to historical performance.

Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, March 28, 2024
OS, Lung cancer, Research, Administration, Conference, Development, Prostate cancer, Survival, Immunotherapy, Fast track (FDA), HGG, Patient, Brain, Standard of care, MD, Society, Insurance, Pancreatic cancer, Clinical trial, Therapy, Breast cancer, SITC, FDA, CADL, Pharmaceutical industry

Research and Development Expenses: Research and development expenses were $7.3 million for the fourth quarter of 2023 compared to $5.0 million for the fourth quarter of 2022, and $24.5 million for the full year 2023 compared to $20.8 million for the full year 2022.

Key Points: 
  • Research and Development Expenses: Research and development expenses were $7.3 million for the fourth quarter of 2023 compared to $5.0 million for the fourth quarter of 2022, and $24.5 million for the full year 2023 compared to $20.8 million for the full year 2022.
  • General and Administrative Expenses: General and administrative expenses were $3.1 million for the fourth quarter of 2023 compared to $3.2 million for the fourth quarter of 2022, and $13.9 million for the full year 2023 compared to $14.1 million for the full year 2022.
  • The change from net other income in the fourth quarter of 2022 to net other expense in the fourth quarter of 2023 was primarily related to the change in the fair value of the Company’s warrant liability.
  • Cash Position: Cash and cash equivalents as of December 31, 2023 were $35.4 million, as compared to $70.1 million as of December 31, 2022.

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, March 12, 2024
Diamond, Research, Administration, EGFR, Mutation, RAF, Development, HGG, Patient, GBM, Neoplasm, Cancer, Lung cancer, BRAF, AACR, Treatment, Investment, NRAS, Clinical trial, Therapy, Poster, FDA, Food, Pharmaceutical industry

The presentation included clinical data from 27 patients with advanced/metastatic NSCLC who received once daily doses ranging from 25mg to 400mg.

Key Points: 
  • The presentation included clinical data from 27 patients with advanced/metastatic NSCLC who received once daily doses ranging from 25mg to 400mg.
  • The trial is currently in dose escalation with an update anticipated in the fourth quarter of 2024.
  • (NCT05786924)
    Cash Position: Black Diamond ended 2023 with approximately $131.4 million in cash, cash equivalents, and investments compared to $122.8 million as of December 31, 2022.
  • Net Loss: Net loss for the fourth quarter of 2023 was $19.4 million, as compared to $21.1 million for the same period in 2022.

Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update

Retrieved on: 
Thursday, February 29, 2024
ONC201, MD, ASCO, Growth, Neuro-Oncology (journal), Manuscript, HGG, Conference, Human, Society, Patient, Journal, Survival, JCO, Pharmaceutical industry

DURHAM, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2023 and provided an operational update.

Key Points: 
  • ET Today –
    DURHAM, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2023 and provided an operational update.
  • Chimerix reported a net loss of $18.2 million, or $0.20 per basic and diluted share, for the fourth quarter of 2023, compared to a net loss of $21.0 million, or $0.24 per basic and diluted share for the fourth quarter of 2022.
  • General and administrative expenses decreased to $5.2 million for the fourth quarter of 2023, compared to $5.3 million for the same period in 2022.
  • Chimerix will host a conference call and live audio webcast to discuss fourth quarter and full-year 2023 financial results and provide a business update today at 8:30 a.m.

Heritage Grocers Group Launches New Loyalty Program

Retrieved on: 
Thursday, February 22, 2024
App Store (iOS/iPadOS), Google Play, HGG, Cardenas (supermarket)

ONTARIO, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Heritage Grocers Group (“Heritage” or “HGG”), one of the leading Hispanic food retailers in the country, is excited to announce the launch of ‘Cardenas Rewards’ – an innovative loyalty program designed to provide even more value and added benefits to loyal customers of Cardenas Markets, an HGG banner company.

Key Points: 
  • ONTARIO, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Heritage Grocers Group (“Heritage” or “HGG”), one of the leading Hispanic food retailers in the country, is excited to announce the launch of ‘Cardenas Rewards’ – an innovative loyalty program designed to provide even more value and added benefits to loyal customers of Cardenas Markets, an HGG banner company.
  • “We are thrilled to offer our new and innovative loyalty program to our dedicated customers and are thankful for their participation,” said Adam Salgado, Chief Marketing Officer of HGG.
  • Similarly, this loyalty program will allow us to tap into data and trends to further customize our offerings to accommodate our customers’ evolving shopping needs.
  • Customers can also sign up for the new loyalty program and start enjoying amazing benefits by visiting https://cardenas-rewards.web.app .

Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments

Retrieved on: 
Thursday, February 15, 2024
Neoplasm, Doctor of Philosophy, Immunotherapy, SCCA, News, Pharmaceutics, Destiny, PR, Optimism, Poster, Anal cancer, Pancreatic cancer, Anal, CEACAM6, Brigham and Women's Hospital, Bristol Myers Squibb, Therapy, Immune system, Pelareorep, International, Breast cancer, Fast track (FDA), Serology, AIO, Hospital, Hope, Principal investigator, HGG, Conference, Safety, Biomarker, Tumor microenvironment, Patent, Clinical trial, Survival, Harvard Medical School, Acute lymphoblastic leukemia, Injection, MSI, MD, BioNTech, FDA, TSX, Cancer, Entrepreneurship, Prevalence, American depositary receipt, Anal canal, Patient, Cone Health Women's Hospital, ONC, Pharmaceutical industry

According to the American Association for Cancer Research "Cancer immunotherapeutics work by unleashing the power of a patient's immune system to fight cancer and, over the last decade, have emerged as one of the most exciting new approaches to cancer treatment."

Key Points: 
  • According to the American Association for Cancer Research "Cancer immunotherapeutics work by unleashing the power of a patient's immune system to fight cancer and, over the last decade, have emerged as one of the most exciting new approaches to cancer treatment."
  • Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) is developing pelareorep, a unique immunotherapy with the power to awaken the immune system and unlock its antitumor potential.
  • It is committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.
  • Bristol-Myers Squibb and Fate Therapeutics are some of the other key patent filers in cancer immunotherapy."

CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma

Retrieved on: 
Tuesday, February 13, 2024
Injection, Doctor of Philosophy, Fast track (FDA), MD, Serology, FDA, Food, Hospital, CADL, Hope, Principal investigator, HGG, Therapy, Tumor microenvironment, Patient, Clinical trial, Survival, Harvard Medical School, Pharmaceutical industry

“Receiving FDA Fast Track Designation for CAN-3110 reinforces the critical need to find effective treatment options for patients with recurrent HGG and further supports the potential of CAN-3110 to address the challenges that the standard of care and conventional therapies have failed to meet,” said Paul Peter Tak, MD, PhD, FMedSci, President and CEO of Candel.

Key Points: 
  • “Receiving FDA Fast Track Designation for CAN-3110 reinforces the critical need to find effective treatment options for patients with recurrent HGG and further supports the potential of CAN-3110 to address the challenges that the standard of care and conventional therapies have failed to meet,” said Paul Peter Tak, MD, PhD, FMedSci, President and CEO of Candel.
  • “As recently published in Nature, a strong local and systemic anti-tumoral response and improved survival in patients with recurrent HGG was observed following a single injection of CAN-3110.
  • Positive HSV-1 serology was a predictor of response and was associated with improved survival (mOS in this population reached 14 months).
  • “With Fast Track Designation, I look forward to the potential of accelerating the development of CAN-3110 and the possibility of bringing this differentiated therapy to patients with recurrent high-grade glioma as we strive to improve outcomes and provide hope for patients and their families.”

Heritage Grocers Group Expands Senior Leadership Team, Adds DeAnn Brunts to Board of Directors

Retrieved on: 
Thursday, February 1, 2024
Growth, Risk management, PwC, Financial management, Initial public offering, Food, MBA, BGS, Small Business Saturday, BSBA, HGG, Benson E. Hill, University, PWC, Management

ONTARIO, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Heritage Grocers Group (“Heritage” or “HGG”), one of the leading Hispanic food retailers in the country, is pleased to announce it has named DeAnn Brunts as a member of its Board of Directors, effective immediately.

Key Points: 
  • ONTARIO, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Heritage Grocers Group (“Heritage” or “HGG”), one of the leading Hispanic food retailers in the country, is pleased to announce it has named DeAnn Brunts as a member of its Board of Directors, effective immediately.
  • With more than 30 years of executive experience in operational, strategic and financial management, Ms. Brunts is a seasoned expert in risk management and governance.
  • “We are thrilled to bring DeAnn onto HGG’s Board of Directors and look forward to all that her expertise and senior knowledge will bring to the company,” said Doug Sanders, Chairman and CEO of Heritage Grocers Group.
  • She currently serves on the Board of Directors for B&G Foods Inc. (NYSE:BGS), a position she has held since 2015, Benson Hill (since 2020) and Claire’s Holdings, LLC (since 2021).

Human medicines European public assessment report (EPAR): Finlee, dabrafenib, Date of authorisation: 15/11/2023, Revision: 1, Status: Authorised

Retrieved on: 
Friday, January 5, 2024
Medical Subject Headings, Diarrhea, Marketing, INN, Fever, Fatigue, ATC, Vincristine, HGG, BRAF, EMA, Xeroderma, Carboplatin, International, Bleeding, Cough, Headache, Nausea, Neutropenia, Language, Neoplasm, Cancer, Mutation, Neutrophil, Radiation, Water, European Medicines Agency, Tablet, MEK, Growth, Select, Patient, Cell, LGG, Safety, Anatomy, Vomiting, IIA, Rash, Medical device

Human medicines European public assessment report (EPAR): Finlee, dabrafenib, Date of authorisation: 15/11/2023, Revision: 1, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Finlee, dabrafenib, Date of authorisation: 15/11/2023, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Finlee, dabrafenib, Date of authorisation: 15/11/2023, Revision: 1, Status: Authorised

Retrieved on: 
Friday, January 5, 2024
Medical Subject Headings, Diarrhea, Marketing, INN, Fever, Fatigue, ATC, Vincristine, HGG, BRAF, EMA, Xeroderma, Carboplatin, International, Bleeding, Cough, Headache, Nausea, Neutropenia, Language, Neoplasm, Cancer, Mutation, Neutrophil, Radiation, Water, European Medicines Agency, Tablet, MEK, Growth, Select, Patient, Cell, LGG, Safety, Anatomy, Vomiting, IIA, Rash, Medical device

Human medicines European public assessment report (EPAR): Finlee, dabrafenib, Date of authorisation: 15/11/2023, Revision: 1, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Finlee, dabrafenib, Date of authorisation: 15/11/2023, Revision: 1, Status: Authorised